This company listing is no longer active
Salud financiera de hoja de balance de CTI BioPharma
Salud financiera controles de criterios 0/6
CTI BioPharma has a total shareholder equity of $-25.3M and total debt of $116.5M, which brings its debt-to-equity ratio to -459.4%. Its total assets and total liabilities are $112.3M and $137.6M respectively.
Información clave
-459.4%
Ratio deuda-patrimonio
US$116.46m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$59.01m |
| Patrimonio | -US$25.35m |
| Total pasivo | US$137.62m |
| Activos totales | US$112.27m |
Actualizaciones recientes sobre salud financiera
Recent updates
Análisis de la situación financiera
Pasivos a corto plazo: CEPS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Pasivo a largo plazo: CEPS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historial y análisis de deuda-patrimonio
Nivel de deuda: CEPS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducción de la deuda: CEPS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: CEPS has less than a year of cash runway based on its current free cash flow.
Pronóstico de cash runway: CEPS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.9% each year